– By Greg Mills, Founder of Analytic Health
In this article we take a brief look into the ever-changing landscape of NHS England and the Clinical Commissioning Groups (CCGs), which are groups of General Practices (GPs) that work together to define the best services for their patients and population1.
In November 2020, NHS England released plans for major structural changes to its organisation. In April 2021 this change took effect when 38 of the CCGs were consolidated to become 9, taking the total number of CCGs down to 106.2
In short, it’s part of a much bigger picture. Since the introduction of the CCGs with the Health and Social Care act of 2012, which aimed to strengthen competition within healthcare by creating a complex, localised structure3, there has been a notable reversal in policy4. From over 200 CCGs, initially, there are now likely to be just 42 by April 2022, as NHS England moves towards its vision of a fully Integrated Care System (ICS).
There are suggested to be many benefits to an ICS, including that the action will support the pandemic recovery by removing unnecessary bureaucracy, empowering local bodies and tackling health inequalities5. However, others question the timing of such a shakeup, as the NHS continues to struggle with Covid-19- one of the biggest challenges in its history. There are also concerns over the loss of local knowledge and community partnerships, even the threat of privatisation that critics say the consolidation may lead to6.
Pharmly Analytics is an application that provides analysis of prescribing habits and healthcare trends around the UK, with maps, graphs and insights aiming to support decision making for a range of organisations. We wrote another article about how the prescribing data can be useful and also some of its challenges here.
As the prescribing data is released 2 months in arrears, we are now gearing up for the new data structure. The April data for England will be released in the middle of June, so as soon as that happens we will switch our setup to include the new CCG structure: 106 CCGs instead of the current 135. The historical data for the 38 CCGs which technically no longer exist will be integrated into the 9 newly introduced CCGs, so no data will be lost.
Please contact us if you have any questions regarding the restructure, how it affects the Pharmly Analytics application, or to collaborate on projects which help to accelerate innovation in healthcare.
– By Greg Mills, Founder of Analytic Health
Generic pharmaceutical shortages have a large impact on the National Health Service (NHS) finances. During a shortage event the Department of Health and Social Care (DHSC) issue an amendment to the original reimbursement price (or drug tariff price), in what is known as the concessionary price.
It is clear to see what the additional spend is during a shortage event: if the price increases from £2 to £10 per pack, for 10 packs, for one month of shortage then there has been an £80 additional spend. However, the more interesting question is what happens after the shortage event; does the price immediately return to its pre-shortage rate? The answer is no, it takes many months, and 73% of the products included in our study are yet to return to the original price. The effect of a pharmaceutical shortage is long-lasting and has a longer-term financial impact.
We built a model to help quantify the impact of these price increases over time, which we made freely available here. The model includes all shortages since January 2015 and will be updated monthly as new prescribing and shortage data are made available.
In the example above you can see a snapshot of the report, focussing on a single product- Chlorpromazine 25mg tablets. The vertical dashed lines represent the start and end of the supply- shortage months. It is clear from this image that the Actual NHS costs soared from £30k per month to a peak of £760k during the second month of the shortage. To date, the financial impact of this shortage has been additional NHS spending of over £20 million, and three years since the end of the shortage, remains 22 times higher per month than the estimated value if the shortage had not occurred.
These additional costs quickly rise for all 214 active ingredients included in the report to a cumulative additional spending total since 2015 of £2.5 billion or around £55 million per month (and continuing to grow).
The financial impact of UK Generic Pharmaceutical Shortages is significant, it is a hugely important area for healthcare, and we welcome further research. If you have any questions or suggestions, please reach out and we will be happy to discuss further.
At Analytic Health we work with a range of organisations to help them understand the pharmaceutical supply situation and provide access to Pharmly- the pharmaceutical market intelligence web application. We are also in the process of making the data used to create this report readily available, both via a web interface and a REST API.
There are certain points to be aware of when viewing this report:
Company affiliations in developing this report: None
People need information from data
The richest source of information in UK healthcare is the prescribing dataset. Understanding the medications prescribed, down to individual GP surgeries, can offer invaluable (anonymised) information which people use to shape regional health policies, monitor disease trends, and guide company portfolio strategies.
All this information is available, however, there is a catch; with over 20million rows of data released by the NHS every month – it is ‘somewhat’ inaccessible without a high-performance computing environment, a team of data scientists and a lot of time on your hands.
So, how can I get the data?
Previously, accessing prescribing data could go something like this…
“Downloading the file… hmm that’s taking some time. While I wait, I’ll try to install the data science software I need to view the data… ok let’s give it a go.”
*Some hours later*
“I can view some data! Now to check the trends- I just need to download 11 more files and I’ll be able to see trends over a year.”
*After manually downloading the 11 files*
“Ah, but that’s at the molecule level for England only, how can I check brand performance, just for tablets, across the whole of the UK?” ?
What’s the problem here?
Clearly, there is a problem here, and the problem is not the analyst, the account manager, or the data scientist. Every person has a unique skill set, and we add value to our team or project, in the best way we can. But we cannot be expected to do everything- I certainly do not manufacture my running shoes before I go out for a jog! So why should you spend your time gathering huge datasets from various places to get that piece of information you need?
How can we help?
At Analytic Health we have gone through the process above so that you and your teams don’t have to. After many years in roles across healthcare, our team has experienced it all, and that is exactly the reason we now so passionately make the information available to our clients.
With enriched datasets* and interactive visualisation tools, we let people do what they do best (which not even the most advanced technology can do) – feel empowered to collaborate with their colleagues while acting upon the information gained from data!
Above you can see part of the prescribing analysis view of our Pharmly web application.
If you would like a demonstration of how we can help you, please contact us and we will happily arrange a call to discuss this with you in more depth.
Stay safe and stay empowered by data!
*the term enriched datasets here refers to cleaned data, merged with other sources, thereby adding value.